Infertility is a devastating late tox of CRC tx. But its risk can be reduced for some, & pre-tx banking may also allow for biologic children in future. Thus, it’s inexcusable that ~60% of #EOCRC pts report their MD NEVER discussed risk of treatment-induced infertility #ASCO21.

Today marks the beginning of my 2nd decade of being a medonc😉 I have taken care of patients, learned & taught GI-onc, and always felt inadequate! The accomplished women in oncology are my motivation to try harder! Thanks Rachna Shroff, MD, MS, FASCO Dawn Hershman Dr. Cathy Eng and many more.

Not everyone with CRCLM needs chemotherapy! A provocative editorial Journal of Clinical Oncology by Dr. Booth and Scott Berry on JCOG0603 calls for an end to "one fits all approach" and asks clinicians to appropriately frame the benefits for pts. Would you agree?

Growth of multidisciplinary care in a population in need of innovation. This is very promising.

Compared to Atezo/Bev, this treatment is easier to administer with less frequent visits. A factor that should not be overlooked in patients’ lives!

I am home from #GI22, reinvigorated and thankful for ASCO to make it happen. Can't wait for the next meeting!

World Cancer Day is a reminder that we have much to learn together! I pledge to continue to learn each and everyday from my patients and from the research community.

Location seems to be the answer to every problem in colorectal cancer!! Left vs. right, upper vs. lower rectum! Kudos to Deborah Schrag and PROSPECT investigators for establishing a path without radiation for many patients who are candidate for sphincter sparing surgeries.

Did you know GI cancers are on the rise in those <50? 🫢 Don’t overlook cancer as a possibility in young individuals with relevant complaints. Prioritizing a #HealthyLifestyle can be a powerful prevention strategy. pubmed.ncbi.nlm.nih.gov/37585204/ AccessHope

Early onset colorectal cancer patients face daily challenges. Are we doing enough? Counseling and lifestyle coaching are not luxuries but necessities. AccessHope City of Hope Fight Colorectal Cancer COLONTOWN meetings.asco.org/abstracts-pres…

Setting expectations when prescribing TAS/bev for refractory CRC patients: Prior therapy impacts the magnitude of benefit of TAS! & TAS/bev may not be better than TAS in the non-trial population! meetings.asco.org/abstracts-pres… meetings.asco.org/abstracts-pres…

Most awaited trial for last decade Peroperative FLOT vs neoadjuvant CROSS for adenocarcinoma of esophagus. What will work the best ? FlOT has Sunk the Cross . ✝️ Median OS 66 months vs 33 months 3 year OS -57.4 % vs 50 .7 % HR of 0.7 FOLT is the winner over Cross . ASCO

Transplant will be a potential consideration for small and selected patient population with mCRC. Can referral to high volume centers help identify these candidates?

Hello Twitter! #myfirstTweet